Seres has completed enrollment for Cohort 2 of the Phase 1b clinical trial of SER-155 in Allo #HSCT patients, bringing us closer to potentially revolutionizing the approach to enteric-derived and bloodstream infections post-transplantation.
ir.serestherapeutics.com/news-releases/…

We are excited to present at #TANDEM24 in San Antonio. Join us at the poster session on Feb 22nd at 6:45pm CST to learn about preliminary data from our currently enrolling Phase 1b study of investigational #microbiome therapeutic SER-155. Learn more: tandem.confex.com/tandem/2024/me…

At Seres, we have been pioneering the development of microbiome therapeutics since 2011. As a #FlagshipFounded company, we took bold leaps in 2023 to transform the lives of patients as we received FDA approval for the first orally administered microbiome-based therapeutic. We're

Attention #FierceNPP attendees! Join our Chief Commercial & Strategy Officer Terri Young today at 9:00AM ET to hear insights and best practices drawn from her experience. #SeresProud Fierce Life Sciences Events

We’re #SeresProud to celebrate the grand opening of our new CLIA lab with a ribbon-cutting ceremony in Lower Gwynedd, Pa.

This new donor screening facility will allow us to continue our mission to transform patients’ lives by revolutionizing #microbiome therapeutics.

Can new advancements in #microbiome therapeutics change how we fight anti-microbial resistance ( #AMR )?

Join Seres’ Chief Scientific Officer Matthew Henn (Matthew Henn) & team at World Anti-Microbial Resistance Congress to discuss potential solutions. See details: bit.ly/45pSoMt #WorldAMRCongress

Antimicrobial resistance ( #AMR ) is one of our greatest public health threats, and the situation is worsening. In STAT we explain why innovative #microbiome therapeutic options may be important for combating antibiotic resistance: bit.ly/3YwVP1w

We’re on a mission to revolutionize #microbiome therapeutics.

This summer, all of our teams came together to collaborate on achieving our goals to better serve patients and celebrate our progress to date. We couldn’t be more #SeresProud of our team!

Join our presentation today at 3 PM EDT at Canaccord Genuity’s 43rd Annual Growth Conference.

Can’t make it? An audio webcast will be available on our website: ir.serestherapeutics.com/news-releases/…

Alongside our collaborator, Nestle Health Science, we are executing the launch our oral microbiome therapy in the United States. In today’s Q2 2023 earnings report, we were pleased to announce highly encouraging initial launch results.

Join Seres today at 8:30 AM EDT for the presentation of our Q2 2023 financial results and operational progress. Join the webcast: ir.serestherapeutics.com/events/event-d…

Our Greater Boston area teams are #SeresProud to volunteer with Circle of Hope, Inc. to create and donate 500 dignity bags of hygiene essentials & 600 COVID kits to help underserved communities stay healthy and safe. Thank you Life Science Cares Boston for helping organize this event!

We’re #SeresProud to announce the publication of our Literature Review Manuscript in Infectious Disease and Therapy. Read more about #Cdiff patient experiences: bit.ly/3K204we

We’re #SeresProud to celebrate the 1st anniversary of the opening of our Quality Control Center of Excellence. Located in Waltham, MA, the center is continuing our work to revolutionize #microbiome therapeutics & transform the lives of patients with unmet needs. Cheers to 1 year!

Congratulations to our 2nd class of Seres Scholars from CRLS! We’re #SeresProud to continue this partnership to promote #DEI in education, as we offer #mentorship , guidance, and opportunities for underserved students from our community.

We hope you spend quality time this #FourthofJuly with the people who bring you joy. From our team at Seres, Happy #IndependenceDay !

#ICYMI We were named one of the TIME 100 Most Influential Companies of 2023 in the ‘Pioneers’ category! We’re #SeresProud of this recognition and excited for the future of the #microbiome . Learn more: bit.ly/3Njt6rZ #TIME100Companies

We’re at the 8th Annual Microbiome_Movement Summit! Our Seres team is there to discuss insights about our pipeline and the future of the #microbiome . Learn more: bit.ly/3NIaT7J #MicrobiomeMovement

The correct answer is C. #Cdiff was first classified as a threat to human health in 1978. Happy #WorldMicrobiomeDay !

We’re #SeresProud to be one of the TIME 100 Most Influential Companies of 2023. Thank you to our colleagues & collaborators for being part of our journey to transform the lives of patients with revolutionary #microbiome therapeutics. bit.ly/3Njt6rZ #TIME100Companies